BioLineRx (BLRX): Q3 2019 Earnings Snapshot


—  BiolineRX (NASDAQ: BLRX) reported third
quarter 2019 operating loss of $6.6 million vs. $6.2 million loss in the
year-over period.

— Net
loss per share was cents per share, narrower than a loss of 6 cents per share
last year, due to higher share count.

R&D expenses rose 11% to $5.6 million, primarily due to costs associated
with the BL-8040 GENESIS and COMBAT/KEYNOTE-202 clinical trials. Results
expected by the end of the year.

shares are down 75% so far this year.

Browse through our earnings calendar
and get all scheduled earnings announcements, analyst/investor conference and
much more!